MariMed Inc. filings document formal disclosures for a cannabis consumer products and retail operator, including annual-meeting governance, operating results and material capital-structure agreements. Recent Form 8-K reports furnish quarterly and annual financial results and describe the restructuring of the company's Series B Convertible Preferred Stock obligation, including related debt and equity components.
Proxy materials disclose stockholder meeting procedures and board-governance matters. The filings also identify MariMed's emerging growth company status and provide public records for transactions, obligations and reporting events connected to its cannabis brand, wholesale distribution and dispensary operations.
Mario Pinho, Chief Financial Officer of Marimed Inc. (MRMD), reported transactions dated 09/15/2025. The filing shows 16,076 restricted stock units (RSUs) treated as acquired and convertible one-for-one into common shares, and 4,574 shares withheld to satisfy tax withholding at a reported price of $0.1374 per share. Following the reported activity the filing lists 157,386 shares beneficially owned directly by the reporting person. The RSUs were originally granted May 9, 2025, and remaining RSUs vest on December 15, 2025, under the award agreement. The Form 4 was signed 09/16/2025.
Ryan Crandall, Chief Commercial Officer of MariMed, Inc. (MRMD), reported equity changes on 09/15/2025. On that date 62,901 restricted stock units (RSUs) vested and are convertible one-for-one into common shares. The issuer withheld 18,462 shares to satisfy tax withholding related to the RSU vesting. Following these transactions the reporting person is shown as beneficially owning 727,667 shares of common stock. The RSUs were originally granted on May 9, 2025, and the remaining portion of that award is scheduled to vest on December 15, 2025 under the award agreement.